1-(4-bromophenylaminocarbonyl)-4,5-diphenyl-3-pyrazolidinone has been researched along with nicotine in 1 studies
Studies (1-(4-bromophenylaminocarbonyl)-4,5-diphenyl-3-pyrazolidinone) | Trials (1-(4-bromophenylaminocarbonyl)-4,5-diphenyl-3-pyrazolidinone) | Recent Studies (post-2010) (1-(4-bromophenylaminocarbonyl)-4,5-diphenyl-3-pyrazolidinone) | Studies (nicotine) | Trials (nicotine) | Recent Studies (post-2010) (nicotine) |
---|---|---|---|---|---|
26 | 0 | 5 | 28,519 | 2,280 | 9,302 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Czachura, JF; Helton, DR; Kallman, MJ; Rasmussen, K | 1 |
1 other study(ies) available for 1-(4-bromophenylaminocarbonyl)-4,5-diphenyl-3-pyrazolidinone and nicotine
Article | Year |
---|---|
The CCK-B antagonist LY288513 blocks the effects of nicotine withdrawal on auditory startle.
Topics: Animals; Hormone Antagonists; Male; Nicotine; Pyrazoles; Rats; Receptors, Cholecystokinin; Reflex, Startle; Substance Withdrawal Syndrome | 1996 |